Structure via PubChem · Public domain (PubChem)
gadobutrol
Sign in to saveAlso known as gadolinium(III) 2,2',2''-(10-((2R,3S )-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Gadobutrol (INN; Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations.
Chemical data
- Formula
- C18H31GdN4O9
- Molecular weight
- 604.7 g/mol
- IUPAC name
- 2-[4,10-bis(carboxylatomethyl)-7-[(2S,3R)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)
- SMILES
- C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@@H](CO)[C@H](CO)O)CC(=O)[O-].[Gd+3]
- InChIKey
- ZPDFIIGFYAHNSK-YYLIZZNMSA-K
- Polar surface area
- 194 Ų
- H-bond donors
- 3
- H-bond acceptors
- 13
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2011
- Admin. routes
- parenteral
- Indications
- congestive heart failure, rheumatoid arthritis, bladder tumor, interstitial cystitis
via ChEMBL · EBI
Research
1,222 papers- Gadobutrol: A Review in Contrast-Enhanced MRI and MRA.Clinical drug investigation · 2018
- Clinical Safety of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations.Investigative radiology · 2024
- Clinical Efficacy of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations.Investigative radiology · 2024
- Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.Radiology · 2023
- Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.Clinical drug investigation · 2013
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 605.133207472
- Has use
- medication
Show 4 more facts
- chemical formula
- C₁₈H₃₁GdN₄O₉
- legal status (medicine)
- boxed warning
- isomeric SMILES
- O=C([O-])CN1CCN(CC(=O)[O-])CCN([C@@H](CO)[C@@H](O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
- canonical SMILES
- O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
via Wikidata · CC0
~12 min read
Encyclopedic overview
16 sectionsContents
- Medical uses
- Adverse effects
- Use in specific populations
- Pregnancy
- Breast-feeding
- Pediatrics
- Geriatrics
- Renally impaired population
- Interactions
- Mechanism of action
- History
- Commercialization
- Research and clinical trials
- Regulatory
- Packaging and purchasing
- References
Gadobutrol (INN; Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations.
Gadobutrol is marketed by Bayer AG as Gadovist, by Bayer HealthCare Pharmaceuticals as Gadavist, and by GE HealthCare as PixxoScan. In India, it is also marketed by Vivere Imaging as Viv-butrol.
Excerpted from Wikipedia’s “gadobutrol” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0